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Introduction
After the discovery of the human immunodeficiency 
vims (HIV), a retrovirus, as the causative agent of the 
acquired immunodeficiency syndrome (AIDS), scien­
tists have been searching exhaustively for drugs that 
attack this virus and inhibit replication. At this time, 
three of these so-called antiretroviral drugs have 
been licensed in the Netherlands: zidovudine (AZT, 
Retrovir®), didanosine (ddl, Videx®) and zalcitabine 
(ddC, Hivid®). Due to the rapid introduction of the 
antiretroviral agents, the clinical pharmacokinetics 
were only sparsely studied at the time these drugs 
became available. The purpose of our studies was to 
investigate the clinical pharmacokinetics of these 
antiretroviral agents in HIV-infected subjects in more 
detail. Special attention was paid to interactions 
between antiretroviral drugs and other drugs.
Bioanalysis
Bioanalytical methods have been developed for four 
antiretroviral agents: immunological assays for zido­
vudine and zalcitabine; high-pressure liquid chroma­
tographic (HPLC) assays for AMT (a metabolite of 
zidovudine), didanosine and stavudine (an investi­
gational antiretroviral agent). A comparison of two 
immunological methods, a radioimmunoassay and a 
fluoroimmunoassay, for the determination of zido­
vudine showed that both methods were similar in 
respect to sensitivity, selectivity, accuracy and repro­
ducibility. Both methods were a clear improvement 
on existing HPLC methods in terms of sensitivity, 
time required for analysis and sample volume. The 
radioimmunoassay is less expensive than the fluoro­
immunoassay and was therefore our method of 
choice for pharmacokinetic studies with zidovudine. 
In vitro experiments had suggested that AMT was 
responsible for zidovudine-induced bone-marrow 
toxicity. Although we could demonstrate by HPLC 
analysis that AMT was indeed present in the plasma 
of HIV-infected patients, its concentrations were 
much lower than expected. It is therefore not likely 
that AMT contributes to bone-marrow suppression 
by zidovudine.
Until recently, no bioanalytical method was avail­
able for the determination of zalcitabine. Zalcitabine 
doses are quite low (0.75 mg three times a day) and 
plasma concentrations are usually not above 
20 ng/ml. Previously published HPLC methods have 
higher detection limits. Combined chromatographic- 
mass-spectrometric assays are more sensitive, but 
require instrumentation not readily available in most 
hospitals. We have developed a radioimmunoassay 
for the determination of zalcitabine, using immuno­
chemicals from Sigma, with the required detection
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limit of 1 ng/ml. Sample pretreatment of plasma, of zidovudine or didanosine in only 1 or 2 plasma 
urine and cerebrospinal fluid (CSF) was carried out samples is sufficient to estimate the area under the 
by solid-phase extraction with silica columns. concentration-time curve (AUC).
Clinical pharmacokinetics
Clinical pharmacokinetic studies have been per­
formed with zidovudine and didanosine, the two 
most widely used agents in the Netherlands at the 
time of our studies. We have conducted a population 
pharmacokinetic study of zidovudine in 68 patients, 
resulting in 95 full pharmacokinetic curves. Clearance 
of zidovudine appeared to be lower in women than 
in men, was decreased in patients with advanced dis­
ease compared with asymptomatic persons, and 
increased proportionally with the patient's body 
weight. In another study we analysed plasma and 
CSF samples of 39 patients with AIDS who under­
went lumbar puncture to establish a diagnosis of a 
neurological disorder (total number of samples: 50). 
It appeared that the concentration-time course was 
different in plasma compared with CSF. Elimination 
of zidovudine from CSF was much slower than from 
plasma, and there was no clear relation between 
zidovudine doses and CSF concentration. This last 
observation may be the explanation of the compar­
able efficacy of currently used low doses of zidovu­
dine in the prevention and treatment of AIDS- 
dementia complex.
The pharmacokinetics of zidovudine were studied 
in a patient with HIV-associated nephropathy and 
different stages of renal dysfunction. Zidovudine 
clearance was only decreased when the renal func­
tion was severely impaired (creatinine clearance 
<10 ml/min). At the same time this patient could no 
longer tolerate the drug because of anaemia.
At the time didanosine was licensed, there was 
only experience with this drug in a sachet formu­
lation. The marketed formulation was a chewable- 
dispersable tablet We have therefore conducted a 
bioequivalence study in 15 HIV-infected patients. The 
tablets showed indeed 20-25% more bioavailability 
than the sachets, as represented in the manufac­
turer's dose recommendations. To our amazement, 
plasma concentrations in patients with a low body 
weight (less than 60 kg) were relatively lower than in 
patients with a higher body weight, despite a 
weight-adjusted dose of didanosine.
The frequent withdrawal of blood samples for 
pharmacokinetic studies is not a sound basis for the 
investigation of pharmacokinetic-pharmacodynamic 
studies. A strategy using so-called limited sampling 
models is less inconvenient for the patient, less la­
borious and less expensive. We have demonstrated 
in two separate investigations that the determination
Drug interactions
In most cases, information about drug-drug inter­
actions is minimal at the time the drugs are licensed. 
For antiretroviral agents this lack of knowledge is a 
matter of even more concern because patients 
usually take a number of drugs concomitantly. We 
have therefore reviewed the literature on drug inter­
actions with antiretroviral agents. In addition, we 
have carried out a number of interaction studies.
We investigated a possible interaction between 
rifampicin and zidovudine or didanosine. Rifampicin, 
widely known as an inductor of metabolizing en­
zymes in the liver, decreased plasma levels of zido­
vudine by 50%, This interaction is probably also 
based on enzyme induction because plasma levels of 
the primary metabolite of zidovudine, zidovudine 
glucuronide, were higher. Rifampicin did not con­
sistently influence didanosine levels, which is in 
agreement with the fact that didanosine is not 
metabolized in the liver. Two studies of the pre­
sumed interaction between paracetamol and zido­
vudine were performed. Although literature sug­
gested otherwise, no pharmacokinetic interaction 
could be demonstrated.
Because combination antiretroviral therapy is be­
coming more popular, antiretroviral drugs may also 
interact with each other. We studied the combi­
nation of zidovudine and didanosine in 5 patients 
with HIV infection. Although plasma concentrations 
of zidovudine were lower in 4 out of the 5 patients 
when both drugs were combined, these differences 
were small, statistically non-significant and probably 
clinically not relevant Didanosine concentrations 
were not altered.
We have investigated the effect of zidovudine on 
phenytoin levels in HIV-infected patients and com­
pared these data with data from HIV-negative per­
sons with epilepsy. No drug interaction between 
zidovudine and phenytoin could be detected. It was 
observed that phenytoin levels were quite different 
from reference data. Possible explanations were a 
higher incidence of liver dysfunction, drug inter­
actions (folic acid, claritromycin) and a lower serum 
albumin level in HIV-infected patients.
Conclusions
The research described in this thesis has given us 
more insight into the various aspects of the clinical 
pharmacokinetic behaviour of antiretroviral agents in
HIV-infected individuals. Especially our knowledge of 
the pharmacokinetics of zidovudine has been en­
hanced, but data for didanosine and zalcitabine are 
still scarce. In all situations, the pharmacokinetics in 
subgroups of patients may be altered, also as a result 
of drug interactions. The next years special attention 
should be paid to pharmacokinetic-pharmaco­
dynamic relationships. The above described research 
has created a basis for this kind of investigation.
Results have also been published in the 
following papers
• Burger DM, Kraaijeveld CL, Meenhorst PL, Mulder JW, Koks 
CHW, Bult A, et at Penetration of zidovudine into the cere­
brospinal fluid of patients infected with human immuno­
deficiency virus. AIDS 1993;7(12):1581 -7.
• Burger DM, Meenhorst PL, Beijnen ]H. Concise overview of 
the clinical pharmacokinetics of dideoxynucleoside antiretro­
viral agents. Pharm World Sri 1995;! 7(2):25-30.
• Burger DM, Meenhorst PL, Koks CHW, Beijnen JH. Drug 
interactions with zidovudine. AIDS 1993;7(4):445-60.
• Burger DM, Meenhorst PL, Koks CHW, Beijnen JH. Pharma­
cokinetic interaction between rifampin and zidovudine. 
Antimicrob Agents Chemother 199B;37(7):1426-31.
• Burger DM, Meenhorst PL, Koks CHW, Beijnen jH. Farmaco- 
kinetiek van zidovudine en enkele andere geneesmiddelen bij 
HIV-geinfecteerden [Pharmacokinetic research in HIV- 
infected patients]. Pharm Weekbl 1993; 128(11 ):345-51.
• Burger DM, Meenhorst PL, Koks CHW, Beijnen jH* Pharma­
cokinetics of zidovudine and acetaminophen in a patient on 
chronic acetaminophen therapy. Ann Pharmacother 1994; 
28(3):327-30.
• Burger DM, Meenhorst PL, Kroon FP, Mulder JW, Koks CHW, 
Bult A, et al. Pharmacokinetic interaction study of zidovudine 
and didanosine. ] Drug Dev 1994;6(4):187-94.
• Burger DM, Meenhorst PL, Mulder jW, Henrichs JH, Frissen 
PHJ, Kroon FP, et al. Substitution of didanosine sachets by 
didanosine chewable tablets: a pharmacokinetic study In 
patients with AIDS. J Acquir immune Defic Syndr 1995;10: 
163-8.
• Burger DM, Meenhorst PL, Mulder JW, Koks CHW, Bult A, 
Beijnen JH. Pharmacokinetics of zidovudine and metabolites 
in a patient with HIV-associated nephropathy and severe 
renal impairment. Drug Invest 1994;7(5):282-7.
• Burger DM, Meenhorst PL, Mulder jW, Kraaijeveld CL, Koks 
CHW, Bult A, et al. Therapeutic drug monitoring of pheny­
toin in patients with the acquired immunodeficiency syn­
drome. Ther Drug Monitor 1994;16(6):616-20.
• Burger DM, Meenhorst PL, ten Napel CHH, Mulder JW, 
Henrichs JH, Frissen PHJ, et al. Limited sampling models for 
the antiretroviral agent didanosine. Eur J Pharm Scl 1995; 
3(1):7-13.
• Burger DM, Meenhorst PL, ten Napei CHH, Muider JW, Neef 
C, Koks CHW, et al. Pharmacokinetic variability of zidovudine 
in HIV-infected Individuals: subgroup analysis and drug inter­
actions. AIDS 1994;8(12):1683-9.
• Burger DM, Meenhorst PL, Underberg WJM, van der Heijde 
JF, Koks CHW, Beijnen JH. Short-term, combined use of 
acetaminophen and zidovudine does not alter the pharma­
cokinetics of either drug. Neth J Med 1994;44:161 -5.
• Burger DM, Rosing H, van Cijn R, Meenhorst PL, van 
Telllngen O, Beijnen JH. Determination of stavudine, a new 
antiretroviral agents, in human plasma by reversed-phase 
high-performance liquid chromatography with ultraviolet 
detection. ] Chromatogr Biomed 1992;584:239-47.
• Burger DM, Rosing H, Koopman FJ, Meenhorst PL, Mulder 
jW, Bult A, et al. Determination of 3'-amino-3'-deoxythymi- 
dine, a cytotoxic metabolite of 3'-azldo-3'~deoxythymidine, 
in human plasma by ion-pair high-performance liquid 
chromatography. J Chromatogr Biomed 1993;622:235-42.
• Burger DM, Rosing H, ten Napei CHH, Duyts T, Meenhorst 
PL, Mulder JW, et al. Application of a radioimmunoassay for 
the determination of zalcitabine (ddC) in human plasma, 
urine, and cerebrospinal fluid. Antimicrob Agents 
Chemother. In press. 1994;38(12):2763-7.
• Burger DM, van Warmerdam LJC, Rosing H, Meenhorst PL, 
Koks CHW, Bult A, et al. Development and validation of 
limited-sampling models for the antiretroviral agent zido­
vudine. Drug invest 1993;6(4):189-97.
